[{"orgOrder":0,"company":"Matrix Biomed","sponsor":"MedStar Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matrix Biomed \/ MedStar Health","highestDevelopmentStatusID":"8","companyTruncated":"Matrix Biomed \/ MedStar Health"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Tempol","moa":"||Superoxide dismutase Cu-Zn (SOD Cu-Zn)||TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matrix Biomed \/ Adamis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Matrix Biomed \/ Adamis Pharmaceuticals"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tempol","moa":"||Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Matrix Biomed \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Matrix Biomed \/ Inapplicable"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Prostate Oncology Specialists","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matrix Biomed \/ Prostate Oncology Specialists","highestDevelopmentStatusID":"8","companyTruncated":"Matrix Biomed \/ Prostate Oncology Specialists"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matrix Biomed \/ University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Matrix Biomed \/ University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"||Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Oncology","graph2":"Undisclosed","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matrix Biomed \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Matrix Biomed \/ Inapplicable"}]